Hematologic Oncology Update cover image

Oncology Today with Dr Neil Love: Key Presentations in Acute Myeloid Leukemia and Myelodysplastic Syndromes from the 2022 ASH Annual Meeting

Hematologic Oncology Update

00:00

Do You Think It Will Take a Phase Three Trial?

The standard care for chemo fit mostly younger but not all adults with a foot three mutant ml is three plus seven plus my best or best on the right of my trial. There is certainly more potent and less toxic foot three inhibitors out there one of which is chrysartanib which is a type two inhibitor so it doesn't hit the foot three TKD but it is very potent against the foot three I.T. mutation. The results were roughly similar to that scene the ratify trial although the patients were older in this trial and there was a survival advantage for patients randomized to chemo quiz, cabrita chemo placebo. It's always better to be uninfined

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app